Our Board of Directors
Doug has a BSc, MBA, and over 30 years of Canadian pharmaceutical experience with extensive sales and marketing experience at several large multinational companies such as Lederle Laboratories, Syntex Inc., Hoffmann-La Roche (Director of Sales, Director of Marketing), Sanofi Inc. (VP, Sales and Marketing). In 2001, he founded, and led as President, Oryx Pharmaceuticals Inc., a Canadian-based specialty pharmaceutical company. Under Doug’s leadership Oryx grew rapidly and was acquired by Sepracor Inc. in 2008 to expand its North American footprint. Doug remained as President from 2008 to 2019 and Sunovion tripled its Canadian sales during his tenure. Throughout his career, Doug has executively led strong entrepreneurial teams to achieve numerous commercially successful launches and founded KYE in 2019.
Ketan is the founder of Tris Pharma. Under his leadership, Tris Pharma has developed many innovative technologies, launched new products, and established itself as a leader among technology-driven pharmaceutical companies. Ketan’s work at Tris has led to many discoveries and inventions. Before founding Tris Pharma, Ketan worked for Capsugel (formerly a division of Pfizer) in sales, marketing, and business development for eight years. Prior to Capsugel, he spent approximately six years as a pharmaceutical scientist for three different large pharmaceutical companies. Ketan is a pharmacist by education and holds an MS degree in Pharmaceutical Sciences from the University of Oklahoma.
Graham started his career in pharmaceuticals in 1992 with Allen and Hanbury’s (now part of GSK), where he held positions in Sales, Marketing and Commercial Information. In 1997 he was promoted to Marketing Manager and managed the established respiratory product portfolio worth in excess of £200M in the UK, of which his achievements include the launching of the first CFC free inhalers in the UK. In 1999, Graham joined Dominion Pharma as the Head of Sales & Marketing. Following the acquisition of Dominion by Pliva, he was promoted to Managing Director and over the following 10 years was responsible for growing the newly named Pliva Pharma Ltd from £5m to £30m turnover. He also put the previously unknown Pliva name onto the map in the UK, and is credited with making the company a leading supplier of ethical medicines to the NHS. Graham set up Aspire Pharma in June 2009 and subsequently Aspire has grown into a real differentiated presence within the industry. Aspire Pharma is one of the fastest growing pharmaceutical companies in the UK today, adopting a sustainable customer focused strategy.
Craig has over 15 years of pharmaceutical industry experience. Prior to co-founding Juno in 2011, Craig worked for Cobalt Pharmaceuticals in its business development group. He was responsible for negotiating product license and supply agreements for Cobalt’s OTC and generic divisions, and was Cobalt’s primary lead on all global M&A transactions.